Stoke Therapeutics, Inc. STOK
Set alert
27.24 USD +0.75 +2.85%
As of Nov 3, 11:54 AM ET
26.63 Day range 27.33
20.32 52-week range 40.22
- YTD
- -14.19%
- 1 year
- +4.35%
- Open
- 26.84
- Prev close
- 26.48
- Mkt cap
- 1.77B
- Vol
- 598.97K
- Avg vol
- 1.02M
- EPS
- -3.81
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 26.63
- High
- 27.33
- Forward P/E
- -7.03
- Beta
- 1.38
- Short ratio
- 10.28
- Inst. own
- 124.91%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 15, 2027
- 50-d avg
- 27.43
- 200-d avg
- 30.92
- 1y target
- 46.38
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 46.38 +70.3% upside
Now 27.24
- Target (low)
- 35.00
- Target (mean)
- 46.38
- Target (high)
- 60.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy2
- Buy12
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 14
- 2 months ago 14
- 3 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.97033 | -1.30 – -0.70 | -0.97 | -0.0% | 7.33M | +422.9% | 12 |
| Next quarter | -1.08 | -1.43 – -0.64 | -0.79 | -37.1% | 6.80M | +9.2% | 6 |
| Current year | -4.05 | -4.29 – -3.94 | -0.12 | -3275.0% | 35.66M | -80.7% | 6 |
| Next year | -3.73 | -5.00 – -2.55 | -4.05 | +7.9% | 47.15M | +32.2% | 12 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Aug 4, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Aug 4, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 4, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Jul 13, 2026 | Goldman Sachs | Initiated | — | Buy |
| May 11, 2026 | BTIG | Reiterated | Buy | Buy |
| Mar 20, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 19, 2026 | BTIG | Reiterated | Buy | Buy |
| Mar 18, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 18, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 17, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 17, 2026 | Needham | Maintained | Buy | Buy |
| Feb 24, 2026 | Wolfe Research | Initiated | — | Outperform |
| Jan 12, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jan 5, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Jan 5, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Dec 15, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 5, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 5, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Nov 5, 2025 | BTIG | Reiterated | Buy | Buy |
| Nov 3, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Oct 13, 2025 | BTIG | Maintained | Buy | Buy |
| Oct 10, 2025 | Needham | Maintained | Buy | Buy |
| Aug 13, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Aug 13, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Jul 18, 2025 | Jefferies | Initiated | — | Buy |
| Jul 1, 2025 | Needham | Reiterated | Buy | Buy |
| May 14, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 9, 2025 | Needham | Reiterated | Buy | Buy |
| Mar 19, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |